

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/699,845	11/04/2003	Sung-Su Jung	8734.248.00 US	4037
	7590 09/20/2007 DNG & ALDRIDGE LLP	EXAMINER		
1900 K STREET, NW			LIN, JAMES	
WASHINGTON, DC 20006			ART UNIT	PAPER NUMBER
			1762	
	•		MAIL DATE	DELIVERY MODE
	•		09/20/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)				
Office Action Summary		10/699,845	JUNG ET AL.				
		Examiner	Art Unit				
		Jimmy Lin	1762				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PE WHICHEVER IS LONGER, FROM - Extensions of time may be available under the after SIX (6) MONTHS from the mailing date - If NO period for reply is specified above, the re- Failure to reply within the set or extended per Any reply received by the Office later than three arned patent term adjustment. See 37 CFR	A THE MAILING DA e provisions of 37 CFR 1.13 of this communication. maximum statutory period w iod for reply will, by statute, ee months after the mailing	ATE OF THIS COMM 36(a). In no event, however, m vill apply and will expire SIX (6) cause the application to beco	UNICATION. lay a reply be timely filed MONTHS from the mailing date of this me ABANDONED (35 U.S.C. \$ 133).				
Status							
1) Responsive to communicati	on(s) filed on <u>17 Au</u>	ugust 2007.					
2a)⊠ This action is FINAL.	This action is FINAL . 2b) This action is non-final.						
closed in accordance with the	ne practice under <i>E</i>	x parte Quayle, 1935	C.D. 11, 453 O.G. 213.	-			
Disposition of Claims							
4) ⊠ Claim(s) <u>1-9 and 11-13</u> is/a. 4a) Of the above claim(s) <u>1-</u> 5) □ Claim(s) is/are allow. 6) ⊠ Claim(s) <u>8,9 and 11-13</u> is/ar 7) □ Claim(s) is/are object 8) □ Claim(s) are subject	<u>7</u> is/are withdrawn ted. re rejected. ted to.	from consideration.					
Application Papers				•			
9) The specification is objected 10) The drawing(s) filed on Applicant may not request that Replacement drawing sheet(s) 11) The oath or declaration is ob	is/are: a) acce any objection to the including the correct	epted or b) objecte drawing(s) be held in ab ion is required if the dra	eyance. See 37 CFR 1.85(a). wing(s) is objected to. See 37	, ,			
Priority under 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachment(s)	:						
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Information Disclosure Statement(s) (PT Paper No(s)/Mail Date		Pape	riew Summary (PTO-413) r No(s)/Mail Date e of Informal Patent Application				

Application/Control Number: 10/699,845 Page 2

Art Unit: 1762

DETAILED ACTION

Claim Rejections - 35 USC § 112

1. Claims 8-9 and 11-13 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The recitation of "the range between the first flow amount and the second flow amount being divided into predetermined parts" (claim 8) is not described in the specification and, thus, presents new matter. The specification only seems to teach that "the second flow amount corresponding to a quantity of sealant dispensings initially available in the syringe is equally divided into a plurality of values" (paragraph [0034] of the original specification as filed).

Additionally, the recitation of "comparing the third flow amount of gas with the divided parts of the range of the first flow amount and the second flow amount of the gas" (claim 8) presents new matter for substantially the same reasons as discussed above. For the purpose of this examination, the claims will be interpreted to have only the second flow amount of gas being divided into predetermined parts.

Claim Rejections - 35 USC § 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later

Application/Control Number: 10/699,845

Art Unit: 1762

invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

4. Claims 8-9 and 11-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hashimoto et al. (U.S. Publication No. 2001/0013920) in view of Applicant's admitted prior art (hereafter, AAPA) and Kawabe et al. (JP 64-059823, one of Applicant's cited references).

Hashimoto teaches a method of making a liquid crystal display (LCD) (abstract). A sealant can be formed on the substrate through a dispenser method [0046].

Hashimoto does not explicitly teach that the dispenser method for the sealant can be performed using a syringe. However, Hashimoto does teach that a liquid crystal composition can be injected onto a substrate through a nozzle of a syringe 42 [0050]. An air pressure source 44 supplies air into the syringe and a controller 43 controls the air pressure source to regulate the volume of the liquid crystal composition to be discharged ([0109]; Fig. 14). It would have been obvious to one of ordinary skill in the art at the time of invention to have dispensed the sealant using the syringe that dispenses the liquid crystal with a reasonable expectation of success because Hashimoto teaches that such a syringe is an operable dispenser for depositing onto an LCD substrate. The selection of something based on its known suitability for its intended use has been held to support a prima facie case of obviousness. Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327, 65 USPQ 297 (1945). Repeated dispensings of the sealant through the syringe by supplying intermediate flow amounts of gas to the syringe would be performed when the syringe is dispensing onto subsequent substrates. The transition to the subsequent substrates would necessarily require intermediate flow amounts of gas.

Hashimoto does not explicitly teach detecting a first flow amount of gas. However, AAPA teaches a need to detect the residual quantity of sealant that remains in a syringe when forming a seal pattern on a substrate. An operator detects an initial charge quantity of the sealant filled in the syringe and calculates a consumed quantity of sealant by calculating a length of the seal pattern during its formation to thereby estimate a residual quantity of the remaining sealant. If the syringe does not have enough sealant, the seal pattern will only be partially formed or not formed at all, causing a defective LCD panel and a decrease in productivity (paragraph [0015] of Applicant's specification). Kawabe teaches a method of accurately detecting the residual

material 13 in a syringe 11. A pressure gauge is installed in the syringe to detect the pressure of the head space. The residual amount can be detected by measuring the time required to reach a predetermined pressure when feeding gas into the syringe (abstract; Fig. 1). It would have been obvious to one of ordinary skill in the art at the time of invention to have used the residual-detecting technique of Kawabe in the process of forming a sealant of Hashimoto because AAPA teaches a need to detect the residual quantity in a syringe and because Kawabe teaches that such a residual-detecting method is operable for use in syringes. One would have been motivated to do so in order to accurately detect if the residual amount of sealant would form a complete seal pattern, thereby avoiding the manufacture of a defective LCD panel.

The method of determining the residual amount as taught by Kawabe is an indirect method of determining a first flow amount as claimed. The method of Kawabe feeds gas into the syringe until a predetermined pressure is reached within the syringe. This detection method determines the residual amount of paste in the syringe. Based on the residual amount, the space or volume not occupied by the paste can be calculated (i.e., residual volume of paste subtracted from the total volume of the syringe). Using the ideal gas law PV = nRT (P is pressure, V is volume, n is the amount or mols of gas, R is a constant, T is temperature), the flow amount of gas (i.e., the variable n) can be calculated because pressure, volume, and temperature are known. The volume corresponds to the space not occupied by the paste. The variable n corresponds to the claimed first flow amount.

Hashimoto does not explicitly teach determining a second flow amount of gas and detecting a third flow amount of gas. Hashimoto only teaches that a controller 43 controls the air pressure source 44 to regulate the volume to be discharged from the syringe [0109]. However, Hashimoto does recognize that the gas source must be controlled in order to dispense a desired amount of dispensing material. In other words, there is a correlation between the amount of gas supplied and the amount of material dispensed. Because the amount of gas supplied to the syringe is controlled, to have measured the actual flow amount of this regulated gas would have been an obvious modification. Therefore, it would have been obvious to one of ordinary skill in the art at the time of invention to have determined the flow amount of gas supplied to the syringe in the method of Hashimoto with a reasonable expectation of success because such a determination is merely a measurement of the amount of gas metered into the syringe.

Hashimoto does not explicitly teach determining a second flow amount of gas by supplying the gas to the syringe filled with the minimum quantity of residual dispensing material that is enough to ensure a previous dispensing but not enough for a subsequent dispensing and the second flow amount divided into predetermined parts. However, the second flow amount of gas can be calculated based on 1) the determination of the residual amount of material in the syringe (i.e., the method of Kawabe), 2) the correlation between the flow amount of gas supplied to the syringe and the amount of material dispensed (i.e., the correlation of Hashimoto), and 3) the amount of material required for each LCD substrate (i.e., an amount that can be calculated according to AAPA). AAPA teaches that it is well known to stop using the syringe when the residual quantity reaches a minimum quantity that will not form a proper seal [0014]-[0015]. The second flow amount can then be determined and can be divided into predetermined parts, wherein the predetermined parts correspond to the flow amount of gas required for deposition of the material on each substrate.

The third flow amount of gas can be determined merely from measuring the total flow amount of gas used during a period of dispensing, correlating to the total amount of material dispensed from the syringe. The residual amount in the syringe can be determined by using simple algebra (i.e., the second flow amount of gas minus the third flow amount of gas).

Therefore, the determination of the second flow amount of gas, the third flow amount of gas, and the residual amount in the syringe can be calculated using known variables and simple algebra. To have performed such calculations would have been an obvious modification to one of ordinary skill in the art at the time of invention.

Claim 9: Hashimoto, AAPA, and Kawabe do not explicitly teach wherein determining the residual quantity includes detecting the divided parts corresponding to the third flow amount of the gas. However, the determination of the number of divided parts that has been used or that remains in the syringe requires simple algebra, and thus, are obvious modifications to one of ordinary skill in the art at the time of invention.

Claim 11: The dispensing material can be a sealant, as discussed above.

Claim 12: Hashimoto teaches that liquid crystal can be dispensed from the syringe, as discussed above, but the combination of references do not explicitly suggest the use of the residual-determining method with liquid crystal. However, one of ordinary skill in the art would

Application/Control Number: 10/699,845

Art Unit: 1762

have recognized that an insufficient amount of liquid crystal dispensed on the substrate would have created a defective LCD panel. Therefore, it would have been obvious to one of ordinary skill in the art at the time of invention to have used the residual-detecting technique in the dispensing of liquid crystal. One would have been motivated to do so in order to have avoided the manufacture of a defective LCD panel.

5. Claim 13 is rejected under 35 U.S.C. 103(a) as being unpatentable over Hashimoto '920 in view of AAPA and Kawabe '823 as applied to claim 8 above, and further in view of Hashimoto et al. (U.S. Publication No. 2003/0083203).

Hashimoto '920, AAPA, and Kawabe are discussed above, but do not explicitly teach that the dispensing material can be silver. However, Hashimoto '203 teaches that conductive fine particles, such as silver, can be dropped onto an LCD substrate from a nozzle [0102]-[0104], wherein the silver is dropped in the form of dots at the outer edges of the image display to prevent breaks and short circuits ([0191]-[0195]); Fig. 8). Hashimoto '920 teaches that materials can be deposited onto an LCD substrate by dropping the material through a nozzle of a syringe. Therefore, it would have been obvious to one of ordinary skill in the art at the time of invention to have connected the upper and lower substrates of Hashimoto '920 using the silver dots of Hashimoto '203 in order to have prevented breaks and short circuits. In addition, it would have been obvious to one of ordinary skill in the art at the time of invention to have dropped the silver dots onto the LCD substrate using the syringe of Hashimoto '920 because Hashimoto '920 teaches that such syringes have nozzles that are suitable for dropping material onto LCD substrates. The selection of something based on its known suitability for its intended use has been held to support a prima facie case of obviousness. Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327, 65 USPQ 297 (1945).

The combination of references does not suggest using the residual-determining method in the process of dispensing silver. However, such a modification is obvious for substantially the same reasons as discussed for claim 12 above.

Response to Arguments

6. Applicant's arguments filed 8/17/2007 have been fully considered but they are not persuasive.

Claims 8-12 and 14 as rejected over Hashimoto '920, AAPA, and Kawabe '823:

Applicant argues on pg. 5-6 that the prior does not teach a combination of elements including "the range between the first flow amount and the second flow amount being divided into predetermined parts" and "determining a residual quantity of the dispensing material remaining in the syringe by comparing the third flow amount of gas with the divided parts of the range of the first flow amount and the second flow amount of the gas". However, such limitations are indefinite and obvious. See discussions above.

Conclusion

7. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jimmy Lin whose telephone number is 571-272-8902. The examiner can normally be reached on Monday thru Friday 8AM - 5:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tim Meeks can be reached on 571-272-1423. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

الا الل

TIMOTHY MEEKS
SUPERVISORY PATENT FYAMINER